Last Updated : Dec 01, 2020 03:50 PM IST | Source: Moneycontrol.com

Oyo hotels has about $1 billion to fund operations until IPO, says founder Ritesh Agarwal

Ritesh Agarwal said Oyo's focus is on getting revenue for per available room to 60-80 percent of pre-COVID-19 pandemic levels across all markets, and India, China, Japan, and Southeast Asia are making progress in reaching that range

The CEO and founder of Oyo Hotels, Ritesh Agarwal
The CEO and founder of Oyo Hotels, Ritesh Agarwal

Oyo Hotels is making progress in recovering from the COVID-19 pandemic fallout and has about $1 billion to fund operations until an initial public offering (IPO), CEO and founder Ritesh Agarwal has told employees.

The 27-year-old founder of the startup, which has endured months of layoffs amid economic losses as the pandemic hammered its business, made the comments in a fireside chat with Oyo board member Troy Alstead.

Like A Boss I Don’t like me? That's ok. We can still happily co-exist if there's respect Oyo’s Ritesh Agarwal

He said his firm's focus is on getting revenue for per available room to 60-80 percent of pre-pandemic levels across all markets. He said India, China, Japan, and Southeast Asia are making progress in reaching that range.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

related news

"We are still not at the best place, a lot more work to be done. We continue to hold close to a billion dollars of cash, including all our group companies," Bloomberg quoted transcript of the discussion between Agarwal and Oyo board member Troy Alstead.

Alstead, former COO of Starbucks Corp., is a independent director on Oyo's board, which also has Gerry Lopez and Munish Varma of SoftBank as members.

Earlier, SoftBank founder Masayoshi Son encouraged and financed Oyo's expansion, which led to operational missteps and soured partnerships. Following this, the Indian startup ended up laying off or furloughing thousands of employees.

Despite these layoffs, Agarwal noted that he had not felt pressure from outside shareholders. He opined that investors have "very strong" representation on the board. Agarwal has also borrowed $2 billion to buy shares in his own firm.

"Our management’s focus is to make sure that we have a well designed, IPO-ready company, available for our shareholders and board members to make the right decision," Agarwal added.
First Published on Dec 1, 2020 03:50 pm